Table 2

Adjusted HRs of infection-related physician claims by multiple sclerosis disease-modifying treatment (DMT)

ModelDMT exposure statusInfection-related physician claimsPYCrude rate per 1000 PY (95% CI)aHR (95% CI)
Unexposed33 94950 312.0674.8 (667.6 to 682.0)reference
1Any DMT38236065.7630.3 (610.4 to 650.6)0.97 (0.91 to 1.04)
2Any first-generation DMT36245841.6620.4 (600.3 to 640.9)0.96 (0.89 to 1.02)
2Any second-generation DMT199224.0888.4 (769.2 to 1020.8)1.47 (1.16 to 1.85)
3Beta-interferon27224478.7607.8 (585.2 to 631.0)0.93 (0.86 to 1.00)
3Glatiramer acetate9021363.0661.8 (619.3 to 706.4)1.04 (0.91 to 1.18)
3Natalizumab153157.9969.0 (821.5 to 1135.3)1.59 (1.19 to 2.11)
3Oral DMTs*4666.2694.9 (508.7 to 926.9)1.17 (0.88 to 1.56)
Any first-generation DMT36245841.6620.4 (600.3 to 640.9)reference
2Any second-generation DMT199224.0888.4 (769.2 to 1020.8)1.53 (1.21 to 1.95)
  • Models were adjusted for sex, age (continuous), index year (continuous), SES (quintiles) and number of comorbidities (none, 1 and ≥2).

  • *Oral DMTs were fingolimod or dimethyl fumarate.

  • aHR, adjusted HR; PY, person-years; SES, socioeconomic status.